Phosphodiesterase 4 (PDE4) is an enzyme that is responsible for the inactivation of cyclic adenosine monophosphate (cAMP).
However, clinical use of these inhibitors has not been achieved yet because of dose-limiting side effects such as nausea and vomiting that restrict therapeutic application. 4) In previous reports, we have described the design and synthesis of bicyclo[3 · 3 · 0]octane derivatives 5) and piperidine derivatives, 6) which are interesting new classes of PDE4 inhibitors with therapeutic potential. Structure activity relationship (SAR) studies of PDE4 inhibitors based on the structural features of Ariflo 1 7) have revealed that its further modification yields a series of PDE4 inhibitors with an improved therapeutic index relative to the classical inhibitor, rolipram 2 ( Fig. 1) . To create efficient new PDE4 inhibitors with a higher therapeutic potential, discovery and evaluation of a new chemical lead with a completely different structure was considered to provide another approach to chemical modification. Here we report on the discovery of two new orally active pyrazolopyridines 5 and 9 (Fig. 2) . SAR data are also presented.
Chemistry
The synthesis of the test compounds listed in Tables 1-3 is outlined in Chart 1. [8] [9] [10] [11] Compounds 27a, d-e, g-i, p, x, and z were commercially available. The other 1-methylpyrazoles, 27c and 27f, were prepared by condensation of methylhydrazine to the corresponding Michael acceptors 33 and 34, respectively. 3-Methylpyrazoles, 27j-o, q-w, and y were prepared from 35 and the corresponding hydrazine derivatives. Michael addition of 27a-z to diethyl ethoxymethylenemalonate gave 28a-z, respectively, after which ring closure was accomplished with phosphorus oxychloride under reflux to afford chlorides 29a-z, respectively. Alkaline hydrolysis of 29a-z gave carboxylic acids 30a-z, respectively. Heating of 30a-z with thionyl chloride, followed by treatment with aqueous ammonia, resulted in production of the amides 31a-z, respectively. Replacement of the chloro moiety of 31a-z with appropriate anilines led to the test compounds 5 and 8-26. N-Methylation of the 3-methoxyaniline moiety afforded 7. Compounds 3, 4, and 6 were prepared from 31a according to the procedure described for preparation of 5 from 31a.
Results and Discussion
A series of pyrazolopyridine derivatives were synthesized and evaluated for inhibition of phosphodiesterase type 4 prepared from U937 cells, 12) which were derived from human monocytes. The results of the assays are expressed as IC 50 values, i.e., the test compound concentration that achieved 50% inhibition relative to the vehicle. Test compounds were also evaluated for inhibition of LPS-induced production of tumor necrosis factor-a (TNF-a) in rats. 13) The results are expressed as ID 50 values, i.e., the dose that showed 50% inhibition relative to the vehicle.
During the course of screening of PDE4 inhibitors, compound 3 showed moderate potency in both the in vitro and in vivo assays. Preliminary SAR data are summarized in Table  1 . As illustrated by the SAR study of 3-7, the meta-substituted aniline analog 5 exhibited the highest activity in both the in vitro and in vivo evaluations. The ortho-isomer 4 also showed moderate in vitro activity, but the para-isomer 6 did not show any in vitro activity at 0.1 mM. N-Methylation of the aniline moiety of 3 afforded 7, which showed no LPDE4 inhibitory activity at 0.3 mM.
We next focused on further optimization of the 1-and 3-methyl moieties of 5. First, optimization was started with chemical modification of the 3-methyl moiety of 5, as shown in Table 2 . Replacement of the 3-methyl moiety of 5 with hydrogen, ethyl, t-butyl, cyclopropyl, or cyclopentyl moieties gave 8-12, respectively, which were nearly 6-fold less potent, nearly equipotent, far less potent, 2-fold more potent, and nearly equipotent as inhibitors of LPDE4, respectively. Among compounds 8-12, it was found that compounds 9 and 12 showed in vivo efficacy at ID 50 values of 3.1 mg/kg, (p.o.) and 2.9 mg/kg, (p.o.), respectively, while 11 showed weaker in vivo activity than 12 despite its higher in vitro potency. Replacement of the 3-methyl moiety of 5 with aromatic substituents such as phenyl, 2-thienyl, and para-chlorophenyl moieties resulted in 13-15, respectively, showing 40-fold, 8-fold, and 40-fold lower LPDE4 inhibitory activity. Compound 14, which exhibited the strongest in vitro activity among compounds 13-15, did not show any in vivo activity at an oral dose of 10 mg/kg, unlike its strong in vitro activity.
Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors
Next, chemical modification of the 1-methyl moiety of 5 was carried out. Replacement of the 1-methyl moiety of 5 with an alkyl moiety, such as an ethyl, n-propyl, n-butyl, n-pentyl, cyclopentyl, or cyclohexyl moiety, gave 16-21, which were nearly 6-fold less potent, equipotent, 2-fold less potent, 1.6-fold less potent, 2-fold less potent, and 20-fold less potent inhibitors of LPDE4, respectively. Compounds 16-20 demonstrated nearly 50% inhibition at an oral dose of 10 mg/kg in the LPS-induced TNF-a production assay in rats, while the 1-cyclohexyl analog 21, which had the weak- est in vitro activity among 16-21, did not show in vivo efficacy at 10 mg/kg. Replacement of the 1-methyl moiety of 5 with an aromatic moiety, such as a phenyl, 1-(ortho-substituted)phenyl, 1-(meta-substituted)phenyl, or 1-(para-substisuted)phenyl moiety, resulted in 22, 23a-c, 24a-c, and 25a-c, respectively. Among these analogs, the 1-phenyl analog 22 demonstrated equipotent in vitro activity to that of 5, but failed to show in vivo efficacy at an oral dose of 10 mg/kg. Introduction of a substituent, such as a chloro, methyl, or methoxy group, into the newly introduced phenyl moiety of 22 was found to be deleterious for both in vitro and in vivo activity, as illustrated by 23a-c, 24a-c, and 25a-c. Two of these compounds, 24a and 25b, were selected for the in vivo evaluation. As a result, compound 24a showed no efficacy at an oral dose of 10 mg/kg, while 25b showed 49% inhibition of TNF-a production. In a final optimization process, the best substituents for position-1 and poisition-3 were selected and incorporated into one molecule. Simultaneous replacement of the 3-methyl moiety of 5 with a cyclopropyl moiety and the 1-methyl moiety with a 1-phenyl moiety led to 26, which showed 2-fold weaker LPDE4 inhibitory activity and was much less potent in vivo (33% inhibition at an oral dose of 10 mg/kg). As shown in Tables 2 and 3 , the above chemical modification of 5 gave compounds 9, 12, 17, and 19, which exhibited nearly equipotent in vitro activity relative to that of 5. Among them, compounds 9 and 12 were more potent and nearly equipotent in vivo, while 17 and 19 showed much weaker in vivo activity relative to 5. In particular, the 1-phenyl analog 22 showed no in vivo efficacy at an oral dose of 10 mg/kg despite its equipotent in vitro activity relative to that of 5.
Further biological evaluation of compounds 3, 5, and 9, which were selected based on their oral activity against LPSinduced TNF-a production, was carried out as shown in Table 4 . These compounds were evaluated for inhibition of slow reacting substance of anaphylaxis (SRS-A)-mediated bronchoconstriction in guinea pigs. 14, 15) The results are expressed as ID 50 values, i.e., the dose that gave 50% inhibition relative to the vehicle. These compounds were also evaluated for inhibition of TNF-a production in human whole blood (HWB) 16) to estimate their clinical potential. The results are expressed as IC 50 values, i.e., the test compound concentration that gave 50% inhibition relative to the vehicle. It was found that the inhibition of bronchoconstriction in actively sensitized guinea pigs was not always consistent with the inhibition of LPS-induced TNF-a production in rats, probably because of differences in pharmacokinetics due to crossspecies comparison. Compounds 5 and 9 demonstrated 50% inhibition of SRS-A-induced bronchoconstriction, with ID 50 values of 6.8 mg/kg, (p.o.) and 7.9 mg/kg, (p.o.), respectively, while their ID 50 values for TNF-a production were 2.4 mg/kg and 3.1 mg/kg, respectively. Compound 3 showed 67% inhibition of SRS-A-mediated bronchoconstriction at an oral dose of 30 mg/kg, and it showed 48% inhibition of TNF-a production in rats at an oral dose of 10 mg/kg. Regarding inhibition of gastric emptying in rats, 17) the ID 50 values of 3 and 5 were higher than that of Ariflo 1, while their IC 50 values for LPS-induced TNF-a production assay in HWB were lower than that of 1. Compounds 3, 5, and 9 were further evaluated to access their side effect profile in a ferret emesis model. It was shown that 3 and 5 did not cause emesis at oral 1100 Vol. 52, No. 9 
a) See corresponding footnotes from doses of up to 30 mg/kg and 10 mg/kg, respectively.
Compounds 3, 5, and 9 demonstrated unexpectedly poor bioavailability (BA) despite their relatively good oral activity (the BA of 3, 5, and 9 was 8.2%, 1.8%, and 3.1%, respectively). One of the reasons for this result was estimated to be ascribed to their potent inhibitory activity of LPS-induced TNF-a production in rat whole blood. For example, compound 5 exhibited IC 50 value of 0.18 mM (data is not given in the table) in rat whole blood.
Subtype selectivity of 5 was also investigated, as displayed in Table 6 . The inhibitory activity of 5 against PDE1, 2, 3, 5, and 6 at 10 mM was 27%, 24%, 54%, 14% and 10%, respectively.
18-21) Accordingly, compound 5 seems to be a subtypeselective PDE4 inhibitor.
Conclusion
Design and synthesis of new orally active subtype-selective PDE4 inhibitors were achieved by structural optimization of chemical lead 3, which was found among our inhouse library. From the compounds tested, compound 5 demonstrated best results with regard to oral activity and side effects, but it showed unexpectedly poor oral bioavailability. Further chemical modification of 5 to improve its bioavailability may be promising to identify an orally bioavailable PDE4 inhibitor with a higher therapeutic potential.
Experimental
General Procedure Analytical samples were homogeneous as confirmed by thin-layer chromatography (TLC), and yielded spectroscopic data consistent with the assigned structures. All 1H-NMR spectra were obtained with a Varian Gemini-200 or MERCURY-300 spectrometer. The chemical shift values are reported in ppm (d) and coupling constants (J) in Hertz (Hz). Fast atom bombardment (FAB) and electron ionisation (EI) mass spectra were obtained with a JEOL JMS-DX303HF or JMS-700 spectrometer. IR spectra were measured using a Perkin-Elmer FTIR 1760X or JASCO FTIR-430 spectrometer. Column chromatography was carried out using silica gel [Merck silica gel 60 (0.063-0.200 mm), Wako Gel C200, Fuji Silysia FL60D, or Fuji Silysia BW-235]. TLC was also performed on silica gel (Merck TLC plate, silica gel 60 F254).
3-Ethyl-1-methyl-1H-pyrazol-5-amine (27c) The following reaction was carried out under argon atmosphere. To a stirred solution of methylhydrazine (3.88 ml, 73.0 mmol) in EtOH (16 ml) was added 33 (8.10 g, 73.0 mmol) under refluxing for 2 h. The reaction mixture was concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (EtOAc) to give 27c (6.84 g, 54.7 mmol, 75%) as a pale orange powder. The following compounds 27f and 27j-o were prepared according to the same procedures as described for the preparation of 27c.
1-(2-Chlorophenyl)-3-methyl-1H-pyrazol-5-amine (27q) The follow- 24 (s, 3H) .
The following compounds 27r-w and 27y were prepared from the corresponding hydrazine derivatives according to the same procedures as described for the preparation of 27q from 35 and 2-chlorophenylhydrazine. The following compounds 28b-z were prepared from the corresponding pyrazole derivatives 27b-z, respectively according to the same procedures as described for the preparation of 28a from 27a.
Diethyl 2-{[(1,3-Dimethyl-1H-pyrazol-5-yl)amino]methylene}malonate (28a)
A mixture of 5-amino-1,3-dimethylpyrazole 27a (20.0 g, 180 mmol) and diethyl ethoxymethylenemalonate (38.9 g, 180 mmol) was stirred at 120°C for 1 h. The reaction mixture was poured into n-hexane and the precipitates were collected by filtration to give 28a (45.3 g, 161 mmol, 89%) as an ivory powder
Ethyl 4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (29a)
The following reaction was carried out under argon atmosphere. A mixture of 28a (28.1 g, 100 mmol) and POCl 3 (140 ml, 1.50 mol) was heated at 120°C under stirring for 18 h. The reaction mixture was poured into ice water and the precipitates were collected by filtration to give 29a (19.6 g, 77.5 mmol, 77%) as an ivory powder. 1 The following compounds 29b-z were prepared from the corresponding enamine derivatives 28b-z, respectively according to the same procedures as described for the preparation of 29a from 28a.
4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic Acid (30a)
To a stirred mixture of 29a (19.6 g, 77.5 mmol) and 85% KOH (50.0 g, 760 mmol) in DME (152 ml) was added H 2 O (120 ml). After being stirred at room temperature for 18 h, the reaction mixture was neutralized with 4 N HCl. The precipitates were collected by filtration and washed with H 2 O to give 30a (17.3 g, 76.9 mmol, 99%) as a white powder. The following compounds 30b-z were prepared from the corresponding ester derivatives 29b-z, respectively according to the same procedures as described for the preparation of 30a from 29a.
4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (31a)
The following reaction was carried out under argon atmosphere. A mixture of 30a (2.00 g, 8.89 mmol) and SOCl 2 (3.24 ml, 44.5 mmol) was heated at 80°C under stirring for 1 h, the reaction mixture was concentrated in vacuo. The resulting residue was used for the next step without further purification.
To a stirred mixture of 28% NH 4 OH (12 ml) and THF (30 ml) was added a solution of the acyl chloride in THF (10 ml) at 0°C. After being stirred at 0°C for 10 min, the reaction mixture was concentrated in vacuo. The residue was poured into H 2 O and extracted with CHCl 3 . The organic layer was dried over Na 2 SO 4 The following compounds 31b-z were prepared from the corresponding carboxylic acid derivatives 30b-z, respectively according to the same procedures as described for the preparation of 31a from 30a.
4-[(3-Methoxyphenyl)amino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (5)
To a mixture of 31a (899 mg, 4.01 mmol) in dioxane (28 ml) was added aniline 32 (1.48 g, 12.0 mmol). After being stirred at 120°C for 2 h, the reaction mixture was poured into Et 2 O and the precipitates were collected by filtration. The resulting powder was triturated with H 2 O to give 5 (686 mg, 2.21 mmol, 55%) as white crystals. mp 259- , DMSO-d 6 ) 10.97 (s, 1H), 8.74 (s, 1H) 
SRS-A Mediated Bronchoconstriction in Guinea Pigs
Male Hartley guinea pigs aged 7 weeks (nϭ5) were actively sensitized by intraperitoneal administration of 1 mg of ovalbumin (OVA) containing 5ϫ10 9 killed Bordetella pertussis organisms on day 0. On day 14, the bronchoconstrictor response was measured using a modified version of the method of Konzett and Rüssler. Bronchoconstriction was induced by an intravenous injection of OVA (0.15-0.5 mg/kg). Sensitized animals were treated with both a cyclooxygenase inhibitor (indomethacin at 5 mg/kg i.v., 3 min before OVA) and an antihistamine (pyrilamine at 1 mg/kg i.v., 1 min before OVA) to ensure that endogenous SRS-A was solely responsible for bronchoconstriction. Test compounds were administered orally at 1 h before antigen challenge. Bronchoconstrictor response was measured for 15 min and the result was represented as the area under the curve (AUC 0-15 min).
Gastric Emptying in Rats Male Sprague-Dawley rats were fasted overnight and were orally administered test compounds or 0.5 w/v% methylcellulose (10 ml/kg). In addition, 0.05 mg/ml of phenol red solution was orally administered in a volume of 1.5 ml at twenty minutes after dosing with the test compounds. Forty minutes after administration of the test compounds, both the cardia and pylorus of the stomach were ligated under anesthesia with sodium pentobarbital (75 mg/kg, i.p.), and then the stomach was isolated without leakage of phenol red. The stomach was cut open and the phenol red solution was drained into a beaker containing 100 ml of 0.1 N NaOH. Part of the solution was filtrated (pore size: 0.45 mm) and the absorbance at 546 nm was measured to determine the amount of dye remaining in the stomach. Then the gastric emptying rate was calculated by the following formula: gastric emptying rateϭ100ϫ(0.75Ϫconcentration of dye in the stomach)/0.75 A value of 0.75 mg/ml was equal to a concentration of 0.05 mg/ml, which was achieved by adding 1.5 ml of phenol red to 100 ml of 0.1 N NaOH. The 50% inhibition rate for gastric emptying by the test compounds was calculated by defining gastric emptying after vehicle administration as 100%.
Inhibitory Activity on LPS-Induced TNF-a a Production in Human Whole Blood Under the supervision of a physician, blood was collected into a heparinized tube (final concentration: 10 U/ml heparin sodium) from a forearm vein in three healthy male donors. A solution of the test compound (10 ml) dissolved in DMSO was added to 180 ml of whole blood, and the mixture was pre-incubated for 30 min at 37°C. Then 10 ml of 2 mg/ml of LPS was added and incubated for 6 h at 37°C, after which the plasma TNF-a concentration was measured with a human TNF-a ELISA kit (DIACLONE). Assays were performed in duplicate at three to four different concentrations of each test compound, and the IC 50 values were determined.
Ferret Emetic Study Male ferrets (weighting about 1.2 kg) were fasted overnight and test compounds were administered orally. Their behavior was observed throughout a 1 h period after gavage. Results were expressed as the number of animals that vomited relative to the animals tested.
